A randomized trial compared short-term androgen deprivation with high-dose radiotherapy (STADT-RT) and high-dose radiation therapy alone in localized prostate cancer.

Prostate cancer is a health issue that impacts individuals worldwide, and choosing the best treatment can be difficult, given the wide array of options available for consideration. One notable ...

A phase 2 trial tested the efficacy of local stereotactic body radiation therapy (SBRT) use after radical prostatectomy.

In intermediate risk prostate cancer patients randomized to short-term ADT and either 70 Gy or 76 Gy, testosterone recovery ...

Quality of life, treatment impact and duration, and the importance of individualized therapy are at the center of international research on androgen deprivation therapy (ADT) for prostate cancer ...

Adding Nubeqa to androgen deprivation therapy improved radiographic progression-free survival in patients with metastatic hormone-sensitive prostate cancer. The combination of Nubeqa (darolutamide) ...

The MARCAP Consortium is the largest independent data repository and statistical analysis team, with Dr. Spratt and Dr. Amar ...

New data presented at the American Urological Association (AUA) annual meeting further supported the use of darolutamide (Nubeqa) in combination with androgen deprivation therapy (ADT) for patients ...

This medication is a beneficial addition to your prostate cancer treatment plan — but it doesn’t come without risks. Here’s how to stay ahead of potential side effects. If you’ve been diagnosed with ...

The National Institute for Health and Care Excellence (NICE) has recommended a new oral hormone therapy for advanced hormone-sensitive prostate cancer. In final draft guidance, NICE said that more ...